 Michael Bauer
Concepts (161)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 21 | 2024 | 2998 | 1.460 |
Why?
| | High-Throughput Nucleotide Sequencing | 5 | 2021 | 169 | 1.400 |
Why?
| | Mutation | 11 | 2021 | 1280 | 0.750 |
Why?
| | Gene Expression Profiling | 7 | 2024 | 1025 | 0.550 |
Why?
| | Software | 6 | 2021 | 276 | 0.520 |
Why?
| | Plasma Cells | 4 | 2021 | 221 | 0.480 |
Why?
| | Neoplasms | 4 | 2020 | 1251 | 0.440 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2014 | 405 | 0.420 |
Why?
| | Expert Systems | 1 | 2012 | 5 | 0.410 |
Why?
| | Natural Language Processing | 1 | 2012 | 45 | 0.400 |
Why?
| | Information Storage and Retrieval | 1 | 2012 | 61 | 0.390 |
Why?
| | Clonal Evolution | 3 | 2016 | 56 | 0.370 |
Why?
| | Sequence Analysis, RNA | 3 | 2024 | 88 | 0.350 |
Why?
| | Genomics | 5 | 2022 | 279 | 0.350 |
Why?
| | Evolution, Molecular | 2 | 2021 | 95 | 0.350 |
Why?
| | Tumor Microenvironment | 3 | 2024 | 222 | 0.300 |
Why?
| | Humans | 30 | 2024 | 50503 | 0.280 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2021 | 833 | 0.280 |
Why?
| | Monoclonal Gammopathy of Undetermined Significance | 2 | 2024 | 112 | 0.240 |
Why?
| | Proto-Oncogene Proteins B-raf | 3 | 2020 | 80 | 0.230 |
Why?
| | Genome, Human | 3 | 2021 | 109 | 0.230 |
Why?
| | Paraffin Embedding | 1 | 2024 | 51 | 0.220 |
Why?
| | Formaldehyde | 1 | 2024 | 49 | 0.220 |
Why?
| | Transcriptome | 2 | 2024 | 313 | 0.210 |
Why?
| | Doxorubicin | 1 | 2024 | 236 | 0.200 |
Why?
| | Paraproteinemias | 1 | 2022 | 72 | 0.200 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 3 | 2021 | 67 | 0.190 |
Why?
| | Early Detection of Cancer | 1 | 2023 | 163 | 0.190 |
Why?
| | Gene Rearrangement | 2 | 2022 | 65 | 0.190 |
Why?
| | Telomere Homeostasis | 1 | 2021 | 10 | 0.190 |
Why?
| | Polycomb Repressive Complex 2 | 1 | 2021 | 46 | 0.190 |
Why?
| | Spliceosomes | 1 | 2021 | 10 | 0.180 |
Why?
| | DNA-Binding Proteins | 2 | 2021 | 418 | 0.180 |
Why?
| | Positron-Emission Tomography | 2 | 2022 | 292 | 0.180 |
Why?
| | RNA Splicing | 1 | 2021 | 38 | 0.180 |
Why?
| | Chromosome Aberrations | 2 | 2022 | 280 | 0.180 |
Why?
| | Alternative Splicing | 1 | 2021 | 53 | 0.180 |
Why?
| | Genes, Tumor Suppressor | 2 | 2021 | 73 | 0.180 |
Why?
| | Ecosystem | 1 | 2021 | 65 | 0.170 |
Why?
| | Phosphoproteins | 1 | 2021 | 115 | 0.170 |
Why?
| | Cell Cycle | 1 | 2021 | 226 | 0.170 |
Why?
| | Prognosis | 6 | 2021 | 1978 | 0.170 |
Why?
| | Exosome Multienzyme Ribonuclease Complex | 1 | 2020 | 12 | 0.170 |
Why?
| | Bone Marrow | 2 | 2022 | 363 | 0.170 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 106 | 0.160 |
Why?
| | Epigenesis, Genetic | 2 | 2020 | 372 | 0.160 |
Why?
| | Genes, myc | 1 | 2019 | 32 | 0.160 |
Why?
| | Algorithms | 4 | 2020 | 625 | 0.160 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2017 | 213 | 0.150 |
Why?
| | Phosphotransferases | 1 | 2018 | 16 | 0.150 |
Why?
| | Mutagenesis | 1 | 2018 | 58 | 0.150 |
Why?
| | Oncogenes | 1 | 2018 | 57 | 0.150 |
Why?
| | Translocation, Genetic | 4 | 2021 | 240 | 0.150 |
Why?
| | Tomography, X-Ray Computed | 1 | 2023 | 1164 | 0.150 |
Why?
| | Transcription Factors | 1 | 2021 | 565 | 0.150 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2018 | 125 | 0.150 |
Why?
| | Neoplasm, Residual | 1 | 2018 | 160 | 0.150 |
Why?
| | Lung Neoplasms | 1 | 2023 | 601 | 0.140 |
Why?
| | Sequence Analysis, DNA | 2 | 2017 | 226 | 0.140 |
Why?
| | Reproducibility of Results | 1 | 2021 | 1197 | 0.140 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2017 | 34 | 0.140 |
Why?
| | Survival Rate | 4 | 2021 | 909 | 0.140 |
Why?
| | Chromosome Deletion | 1 | 2017 | 134 | 0.130 |
Why?
| | Disease Progression | 4 | 2021 | 829 | 0.130 |
Why?
| | Flow Cytometry | 1 | 2018 | 474 | 0.130 |
Why?
| | Epigenomics | 1 | 2015 | 68 | 0.120 |
Why?
| | Cross-Linking Reagents | 1 | 2014 | 41 | 0.120 |
Why?
| | Protein Interaction Mapping | 1 | 2014 | 37 | 0.120 |
Why?
| | ras Proteins | 1 | 2014 | 64 | 0.110 |
Why?
| | Clone Cells | 3 | 2021 | 70 | 0.110 |
Why?
| | Proto-Oncogene Proteins | 1 | 2014 | 145 | 0.110 |
Why?
| | Aged | 7 | 2023 | 9741 | 0.110 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2018 | 578 | 0.110 |
Why?
| | Mass Spectrometry | 1 | 2014 | 285 | 0.110 |
Why?
| | RNA | 1 | 2013 | 163 | 0.100 |
Why?
| | Male | 9 | 2024 | 25907 | 0.100 |
Why?
| | Computational Biology | 2 | 2014 | 215 | 0.100 |
Why?
| | Aged, 80 and over | 4 | 2021 | 3226 | 0.100 |
Why?
| | Female | 9 | 2024 | 27081 | 0.090 |
Why?
| | Middle Aged | 6 | 2023 | 12611 | 0.090 |
Why?
| | Follow-Up Studies | 3 | 2021 | 2242 | 0.090 |
Why?
| | Internet | 1 | 2012 | 259 | 0.090 |
Why?
| | Databases, Factual | 1 | 2012 | 673 | 0.080 |
Why?
| | Gene Dosage | 2 | 2020 | 74 | 0.080 |
Why?
| | DNA, Neoplasm | 2 | 2020 | 143 | 0.080 |
Why?
| | DNA Mutational Analysis | 2 | 2020 | 175 | 0.080 |
Why?
| | DNA Copy Number Variations | 2 | 2021 | 109 | 0.080 |
Why?
| | Survival Analysis | 2 | 2021 | 661 | 0.070 |
Why?
| | Genomic Instability | 2 | 2018 | 90 | 0.070 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2022 | 629 | 0.060 |
Why?
| | Transplantation, Autologous | 2 | 2018 | 481 | 0.060 |
Why?
| | Tissue Fixation | 1 | 2024 | 34 | 0.060 |
Why?
| | Killer Cells, Natural | 1 | 2024 | 106 | 0.060 |
Why?
| | Myeloid Progenitor Cells | 1 | 2023 | 17 | 0.060 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2024 | 125 | 0.050 |
Why?
| | Adult | 4 | 2021 | 13577 | 0.050 |
Why?
| | Signal Transduction | 2 | 2021 | 1624 | 0.050 |
Why?
| | Radiation Dosage | 1 | 2023 | 162 | 0.050 |
Why?
| | Phylogeny | 1 | 2022 | 236 | 0.050 |
Why?
| | T-Lymphocytes | 1 | 2023 | 325 | 0.050 |
Why?
| | Myocardium | 1 | 2024 | 445 | 0.050 |
Why?
| | Mutation Rate | 1 | 2021 | 35 | 0.050 |
Why?
| | Cyclin D2 | 1 | 2020 | 20 | 0.040 |
Why?
| | Aneuploidy | 1 | 2020 | 18 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-maf | 1 | 2020 | 19 | 0.040 |
Why?
| | Chromosomes, Human, Pair 4 | 1 | 2020 | 30 | 0.040 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2020 | 49 | 0.040 |
Why?
| | Histone Code | 1 | 2020 | 30 | 0.040 |
Why?
| | Cyclin D1 | 1 | 2020 | 52 | 0.040 |
Why?
| | Incidence | 1 | 2023 | 1032 | 0.040 |
Why?
| | Chromosomes, Human, Pair 14 | 1 | 2020 | 66 | 0.040 |
Why?
| | Rats, Sprague-Dawley | 1 | 2024 | 1585 | 0.040 |
Why?
| | Lymphoma, Follicular | 1 | 2020 | 21 | 0.040 |
Why?
| | Alleles | 1 | 2021 | 256 | 0.040 |
Why?
| | Protein Disulfide-Isomerases | 1 | 2019 | 14 | 0.040 |
Why?
| | Genes, Immunoglobulin Heavy Chain | 1 | 2019 | 12 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2023 | 1398 | 0.040 |
Why?
| | Multivariate Analysis | 1 | 2021 | 583 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2021 | 641 | 0.040 |
Why?
| | Animals | 2 | 2024 | 13124 | 0.040 |
Why?
| | Risk Factors | 2 | 2018 | 3724 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2019 | 231 | 0.040 |
Why?
| | Remission Induction | 1 | 2018 | 208 | 0.040 |
Why?
| | Histones | 1 | 2020 | 297 | 0.040 |
Why?
| | Loss of Heterozygosity | 1 | 2018 | 75 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2020 | 465 | 0.040 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 320 | 0.040 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2018 | 46 | 0.040 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2018 | 57 | 0.040 |
Why?
| | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2017 | 8 | 0.040 |
Why?
| | Rats | 1 | 2024 | 3292 | 0.040 |
Why?
| | Arkansas | 1 | 2023 | 1985 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2017 | 27 | 0.040 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2018 | 88 | 0.040 |
Why?
| | Genome-Wide Association Study | 1 | 2018 | 163 | 0.040 |
Why?
| | STAT3 Transcription Factor | 1 | 2017 | 77 | 0.040 |
Why?
| | Fibroblast Growth Factors | 1 | 2017 | 45 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2018 | 5283 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2017 | 155 | 0.030 |
Why?
| | Amino Acid Sequence | 1 | 2018 | 574 | 0.030 |
Why?
| | Genes, ras | 1 | 2016 | 43 | 0.030 |
Why?
| | Genes, p53 | 1 | 2016 | 49 | 0.030 |
Why?
| | NF-kappa B | 1 | 2018 | 315 | 0.030 |
Why?
| | DNA Methylation | 1 | 2020 | 550 | 0.030 |
Why?
| | Models, Genetic | 1 | 2016 | 172 | 0.030 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2016 | 140 | 0.030 |
Why?
| | Stem Cell Transplantation | 1 | 2016 | 179 | 0.030 |
Why?
| | Succinimides | 1 | 2014 | 7 | 0.030 |
Why?
| | Recurrence | 1 | 2016 | 659 | 0.030 |
Why?
| | Time Factors | 1 | 2021 | 2935 | 0.030 |
Why?
| | Protein Multimerization | 1 | 2014 | 51 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2016 | 735 | 0.030 |
Why?
| | Software Design | 1 | 2013 | 12 | 0.030 |
Why?
| | Molecular Sequence Annotation | 1 | 2013 | 27 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1000 | 0.030 |
Why?
| | Peptides | 1 | 2014 | 221 | 0.030 |
Why?
| | Mice | 1 | 2023 | 5687 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2016 | 985 | 0.020 |
Why?
| | Cell Line | 1 | 2013 | 988 | 0.020 |
Why?
| | Breast Neoplasms | 1 | 2020 | 1201 | 0.020 |
Why?
| | Systems Biology | 1 | 2009 | 32 | 0.020 |
Why?
|
|
Bauer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|